Guggenheim keeps Merck at Buy and lifts target to $171
Guggenheim reaffirmed its Buy rating on Merck & Co and raised its price target by $1 to $171, a 0.6% increase, per TradingView citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Guggenheim reaffirmed its Buy rating on Merck & Co and raised its price target from $170 to $171, a 0.6% increase, TradingView reports. The new target implies 16.9% upside from the October 29 close of $146.33.
According to the same source, the five latest analyst notes over the past 30 days put Merck price targets between $145 and $180. Barclays holds Overweight with a $180 target, while Citigroup, RBC Capital and Cantor Fitzgerald stay neutral with $145 targets.
why it matters
A one-dollar increase in a price target is usually a routine event and rarely moves the stock. The spread of targets across brokers is the more telling signal for the market. Data is provided by Benzinga and is not investment advice.
tags
instruments
sources
- Guggenheim maintains Merck & Co at Buy, raises price target to $171 from $170 — TradingView, 30 October 2026 at 13:10 UTC
- Guggenheim maintains Genmab at Buy, raises price target to $80 from $58 — TradingView, 30 October 2026 at 13:15 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗